| First report of drug-induced esophagitis by deferasirox. | |
| | |
MedLine Citation:
|
PMID: 22547195 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Deferasirox is a new oral iron chelator used to treat transfusional iron overload. We describe a case of a 79-year-old man with myelodysplastic syndrome (MDS) who developed esophagitis induced by deferasirox. He repeatedly received multiple red blood cell transfusions after a diagnosis of MDS. Two years after starting red blood cell transfusions, he was diagnosed with iron overload, and was then started on deferasirox at 1 g/day with about 400 ml of water. He was admitted to our institution because he was unable to swallow his own saliva 1 month after starting deferasirox. Esophagogastroendoscopy revealed white-coated mucosa covering the entire esophagus. A component analysis of biopsy specimens using high-performance liquid chromatography identified deferasirox. Symptoms resolved within about 2 weeks after discontinuing deferasirox, and repeated endoscopy showed marked improvement of esophagitis after 1 month. Re-administration of deferasirox was not attempted. Unfortunately, the patient died due to pneumonia 6 months after administration of deferasirox was started. This is the first report of drug-induced esophagitis associated with deferasirox. |
| | |
Authors:
|
Takeshi Yoshikawa; Takeshi Hara; Hiroshi Araki; Hisashi Tsurumi; Masami Oyama; Hisataka Moriwaki |
Related Documents
:
|
1316075 - Efficacy of lomefloxacin as compared to norfloxacin in the treatment of uncomplicated u... 18193385 - An audit of efficacy and toxicity of teicoplanin versus vancomycin in febrile neutropen... 1337525 - Uncomplicated urinary tract infections: lomefloxacin versus trimethoprim/sulphamethoxaz... 7027925 - Treatment of uncomplicated urinary tract infections with trimethoprim versus sulfisoxaz... 9344575 - Effect of stereotaxic intrastriatal cografts of autologous adrenal medulla and peripher... 20922625 - Long-term outcomes following repair or replacement in degenerative mitral valve disease. |
Publication Detail:
|
Type: Case Reports; Journal Article Date: 2012-05-01 |
Journal Detail:
|
Title: International journal of hematology Volume: 95 ISSN: 1865-3774 ISO Abbreviation: Int. J. Hematol. Publication Date: 2012 Jun |
Date Detail:
|
Created Date: 2012-06-15 Completed Date: 2012-11-08 Revised Date: 2013-06-03 |
Medline Journal Info:
|
Nlm Unique ID: 9111627 Medline TA: Int J Hematol Country: Japan |
Other Details:
|
Languages: eng Pagination: 689-91 Citation Subset: IM |
Affiliation:
|
Department of Internal Medicine, Kisogawa Municipal Hospital, Aichi, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Benzoates
/
adverse effects*,
therapeutic use Blood Transfusion / adverse effects Esophagitis / chemically induced*, diagnosis, pathology Humans Iron Chelating Agents / adverse effects* Iron Overload / complications, drug therapy Male Myelodysplastic Syndromes / complications, therapy Triazoles / adverse effects*, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Benzoates; 0/Iron Chelating Agents; 0/Triazoles; V8G4MOF2V9/deferasirox |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: ABSTRACTS OF THE PROCEEDINGS OF THE 31st ANNUAL SCIENTIFIC CONFERENCE OF THE SOCIETY.
Next Document: Initial low-dose valganciclovir as a preemptive therapy is effective for cytomegalovirus infection i...